Application No.: 09/936,758

Ia

Page 4

$$(R^{1})_{m}$$
 $(R^{2})_{n}$ 
 $(R^{2})_{q}$ 
 $(R^{2})_{q}$ 
 $(R^{2})_{q}$ 
 $(R^{2})_{q}$ 

wherein X is -NHCO- or -CONH-;

m is 1, 2 or 3;

at least one R<sup>1</sup> is a piperazinyl group and any other R<sup>1</sup> that is present is selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (1-6C)alkanoylamino, N-(1-6C)alkyl-(1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N-(1-6C)alkylsulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxycarbonyl-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy, carbamoyl-(1-6C)alkoxy, N-(1-6C)alkylcarbamoyl-(1-6C)alkoxy, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, halogeno-(2-6C)alkylamino, hydroxy-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbonyl-(1-6C)alkylamino, carbamoyl-(1-6C)alkylamino,

ATTORNEY DOCKET NO.: 056291-5044 Application No.: 09/936,758

Page 5

 $\underline{N}$ -(1-6C)alkylcarbamoyl-(1-6C)alkylamino,  $\underline{N}$ ,  $\underline{N}$ -di-[(1-6C)alkyl]carbamoyl-

(1-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino,

di-[(1-6C)alkyl]amino-(2-6C)alkylamino, N-(1-6C)alkyl-halogeno-(1-6C)alkylamino,

N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino, N-(1-6C)alkyl-

(1-6C)alkoxy-(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-carboxy-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-(1-6C)alkoxycarbonyl-

(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-carbamoyl-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-

N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-amino-

(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino,

N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, halogeno-(2-6C)alkanoylamino,

hydroxy-(2-6C)alkanoylamino, (1-6C)alkoxy-(2-6C)alkanoylamino,

cyano-(2-6C)alkanoylamino, carboxy-(2-6C)alkanoylamino,

(1-6C)alkoxycarbonyl-(2-6C)alkanoylamino, carbamoyl-(2-6C)alkanoylamino,

 $\underline{N}$ -(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino,  $\underline{N},\underline{N}$ -di-[(1-6C)alkyl]carbamoyl-

(2-6C)alkanoylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-

(2-6C)alkanoylamino, di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino and

(1-3C)alkylenedioxy,

and wherein any of the R<sup>1</sup> substituents defined hereinbefore which comprises a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,

and wherein any piperazinyl group in a R¹ substituent may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl,

BX



Page 6

and wherein any piperazinyl group in a R<sup>1</sup> substituent may optionally bear 1 or 2 oxo or thioxo substituents;

n is 0, 1 or 2;

R<sup>2</sup> is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy,

(1-6C)alkoxycarbonyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy,

(1-6C)alkylamino or di-[(1-6C)alkyl]amino;

R<sup>3</sup> is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy;

q is 0, 1, 2, 3 or 4; and

Q is aryl, optionally substituted with 1, 2 or 3 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N.N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy,

(1-6C)alkanoylamino, N-(1-6C)alkyl-(1-6C)alkanoylamino,

N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,

(1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino,

halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,

di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxycarbonyl-

(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl,

 $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, halogeno-(2-6C)alkoxy,

hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy,

carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy,

carbamoyl-(1-6C)alkoxy, N-(1-6C)alkylcarbamoyl-(1-6C)alkoxy,

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy,


(1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy,

halogeno-(2-6C)alkylamino, hydroxy-(2-6C)alkylamino,

(1-6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino,

carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbonyl-(1-6C)alkylamino,

BX CON



Page 7

carbamoyl-(1-6C)alkylamino, N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino,

(1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-

(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-cyano-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-carboxy-(1-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-(1-6C)alkyl-carbamoyl-(1-6C)alkyl-carbamoyl-

(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl- $\underline{N}$ -(1-6C)alkylcarbamoyl-(1-6C)alkylamino,

N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-

(2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino,

(1-6C)alkoxy-(2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino,

carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino,

carbamoyl-(2-6C)alkanoylamino, N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(2-6C)alkanoylamino, amino-(2-6C)alkanoylamino,

 $(1-6C) alkylamino-(2-6C) alkanoylamino, \\ di-[(1-6C)alkyl] amino-2-6C) alkanoylamino, \\ di-[(1-6C)alkyl] amino-2$ 

aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino,

 $\underline{N}$ -(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-aryl-

(1-6C)alkylamino, aroylamino, arylsulphonylamino,  $\underline{N}$ -arylsulphamoyl,

aryl-(2-6C)alkanoylamino and (1-3C)alkylenedioxy,

and wherein any of the substituents on Q defined hereinbefore which comprises a

CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,

and wherein any aryl group in a substituent on Q may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,

 $\underline{N}, \underline{N}$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino,

By

Application No.: 09/936,758

Page 8

di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl;

or a pharmaceutically-acceptable salt or <u>in-vivo</u>-cleavable ester thereof.

## 2. (Amended) An amide derivative of the Formula Ib

$$(R^{1})_{m}$$
 $(R^{2})_{n}$ 
 $(R^{2})_{q}$ 
 $(R^{2})_{q}$ 

wherein m is 1, 2 or 3;

at least one R¹ is piperazinyl group and any other R¹ group that is present is selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N-N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkylsulphamoyl, (1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, amino-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkyl, n-(1-6C)alkoxy, n-(1-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, n-(1-6C)alkoxy, n-(1-

Bit



Page 9

amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, halogeno-(2-6C)alkylamino, hydroxy-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbonyl-(1-6C)alkylamino, carbamoyl-(1-6C)alkylamino, N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino, N-(1-6C)alkyl-carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino, N-(1-6C)alkyl-carbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino, (1-6C)alkoxy-(2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino, carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino, carbamoyl-(2-6C)alkanoylamino, N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino, N,N-di-[(1-6C)alkyl]carbamoyl-(2-6C)alkanovlamino, amino-(2-6C)alkanovlamino, (1-6C)alkylamino-(2-6C)alkanoylamino, di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino and

and wherein any of the R<sup>1</sup> substituents defined hereinbefore which comprises a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,

and wherein any piperazinyl group in a R<sup>1</sup> substituent may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,

By

(1-3C)alkylenedioxy,

ATTORNEY DOCKET NO.: 056291-5044 Application No.: 09/936,758

Page 10

```
halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,
cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,
di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl,
```

n is 0, 1 or 2;

R<sup>2</sup> is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy,

(1-6C)alkoxycarbonyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy,

(1-6C)alkylamino or di-[(1-6C)alkyl]amino;

R<sup>3</sup> is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy;

q is 0, 1, 2, 3 or 4; and

Q is aryl, optionally substituted with 1, 2 or 3 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl,

(1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,

(2-6C)alkanoyloxy, (1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,

N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-

(1-6C)alkanesulphonylamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,

(1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl,

(1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl,

(1-6C)alkoxycarbonyl-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-

(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, halogeno-(2-6C)alkoxy,

hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy,

carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy, carbamoyl-(1-6C)alkoxy,

N-(1-6C)alkylcarbamoyl-(1-6C)alkoxy, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy,

amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-

(2-6C)alkoxy, halogeno-(2-6C)alkylamino, hydroxy-(2-6C)alkylamino,

(1-6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino,

(1-6C)alkoxycarbonyl-(1-6C)alkylamino, carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N,N-di-[(1-6C)alkyl]carbamoyl-

(1-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino,

Application No.: 09/936,758

Page 11

 $\underline{N}$ -(1-6C)alkyl-hydroxy-(2-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-(1-6C)alkoxy-

(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino, N-(1-6C)alkyl-carboxy-

(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino,

 $\underline{N}$ -(1-6C)alkyl-carbamoyl-(1-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl- $\underline{N}$ -(1-6C)alkylcarbamoyl-

(1-6C)alkylamino, N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino,

N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-

(2-6C)alkylamino,  $\underline{N}$ -(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino,

halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino,

(1-6C)alkoxy-(2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino,

carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino,

carbamoyl-(2-6C)alkanoylamino, N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino,

N,N-di-[(1-6C)alkyl]carbamoyl-(2-6C)alkanoylamino, amino-(2-6C)alkanoylamino,

(1-6C)alkylamino-(2-6C)alkanoylamino, di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino,

aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino, N-(1-6C)alkyl-arylamino,

aryl-(1-6C)alkylamino, N-(1-6C)alkyl-aryl-(1-6C)alkylamino, aroylamino,

arylsulphonylamino, N-arylsulphamoyl, aryl-(2-6C)alkanoylamino and

(1-3C)alkylenedioxy,

and wherein any of the substituents on Q defined hereinbefore which comprises a CH<sub>2</sub> group which is attached to 2 carbon atoms or a CH<sub>3</sub> group which is attached to a carbon atom may optionally bear on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,

and wherein any aryl group in a substituent on Q may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,

halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl,

By

Application No.: 09/936,758

Page 12

(1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl;

or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof.

3. (Amended) An amide derivative of the Formula Ia according to claim 1 wherein X is -NHCO- or -CONH-;

R<sup>3</sup> is hydrogen, methyl or ethyl;

m is 1 or 2;

at least one R<sup>1</sup> is a piperazinyl group and any other R<sup>1</sup> group that is present is selected from hydroxy, fluoro, chloro, bromo, trifluoromethyl, cyano, methyl, ethyl, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino, diethylamino, methylaminomethyl, ethylaminomethyl, dimethylaminomethyl, diethylaminomethyl, 2-aminoethoxy,

3-aminopropoxy, 2-methylaminoethoxy, 2-ethylaminoethoxy, 3-methylaminopropoxy,

3-ethylaminopropoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy,

3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-aminoethylamino,

3-aminopropylamino, 2-methylaminoethylamino, 2-ethylaminoethylamino,

3-methylaminopropylamino, 3-ethylaminopropylamino, 2-dimethylaminoethylamino,

2-diethylaminoethylamino, 3-dimethylaminopropylamino, 3-diethylaminopropylamino,

 $\underline{N}$ -(2-aminoethyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(3-aminopropyl)- $\underline{N}$ -methylamino,

 $\underline{N}$ -(2-methylaminoethyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(2-ethylaminoethyl)- $\underline{N}$ -methylamino,

 $\underline{N}$ -(3-methylaminopropyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(3-ethylaminopropyl)- $\underline{N}$ -methylamino,

 $\underline{N}$ -(2-dimethylaminoethyl)- $\underline{N}$ -methylamino,  $\underline{N}$ -(2-diethylaminoethyl)- $\underline{N}$ -methylamino,

 $\underline{N}$ -(3-dimethylaminopropyl)- $\underline{N}$ -methylamino and

 $\underline{N}$ -(3-diethylaminopropyl)- $\underline{N}$ -methylamino;

n is 0 or 1;

R<sup>2</sup> is fluoro, chloro, bromo, methyl or ethyl;

q is 0; and

Q is phenyl, indenyl, indanyl, tetrahydronaphthyl or fluorenyl, which optionally bears 1 or 2 substituents selected from hydroxy, fluoro, chloro, trifluoromethyl, cyano, amino, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy, methylenedioxy,

Application No.: 09/936,758

Page 13

methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, N-methylacetamido, methanesulphonamido, N-methylmethanesulphonamido, aminomethyl, methylaminomethyl, ethylaminomethyl, dimethylaminomethyl, diethylaminomethyl, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 2-ethoxyethoxy, 3-methoxypropoxy, 3-ethoxypropoxy, 2-aminoethoxy, 3-aminopropoxy, 2-methylaminoethoxy, 2-ethylaminoethoxy, 3-methylaminopropoxy, 3-ethylaminopropoxy, 2-diethylaminoethoxy, 3-diethylaminopropoxy, 3-diethylaminopropoxy and phenyl, and wherein any phenyl group in a substituent on Q may optionally bear 1 or 2 substituents selected from fluoro, chloro, methyl and methoxy;

Bit

5. (Amended) An amide derivative of the Formula Ib according to claim 2 wherein  $R^3$  is hydrogen or methyl;

m is 1 and R<sup>1</sup> is 4-methylpiperazin-1-yl;

or a pharmaceutically-acceptable salt thereof.

n is 0 or 1;

R<sup>2</sup> is methyl;

q is 0; and

Q is phenyl which bears 1 or 2 substituents selected from fluoro, chloro, trifluoromethyl, methoxy, cyclopentyloxy and acetamido, or Q is 1-fluorenyl;

or a pharmaceutically-acceptable salt thereof.

6. (Amended) An amide derivative of the Formula Ib according to claim 2 wherein R<sup>3</sup> is hydrogen or methyl;

m is 1 and R<sup>1</sup> is 4-methylpiperazin-1-yl;

n is 0 or 1;

R<sup>2</sup> is 6-methyl;

q is 0; and

Q is 1-fluorenyl or 3-acetamidophenyl;

or a pharmaceutically-acceptable salt thereof.

7. (Amended) An amide derivative of the Formula Ib according to claim 2 wherein R<sup>3</sup> is hydrogen;

m is 1 and R<sup>1</sup> is 4-methylpiperazin-1-yl;

n is 0 or 1;

R<sup>2</sup> is 6-methyl or 6-fluoro;

q is 0; and

Q is 2-methoxyphenyl, 3-ethoxyphenyl, 3-(1,1,2,2-tetrafluoroethoxy)phenyl,

3,4-methylenedioxyphenyl, 3-acetamidophenyl or 3-(4-fluorophenyl)phenyl; or a pharmaceutically-acceptable salt thereof.

By.

8. (Amended) An amide derivative of the Formula Ia according to claim 1, which is 3-[5-(3-acetamidobenzamido)-2-methylphenyl]-6-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-4-one, or a pharmaceutically-acceptable salt thereof.

9. (Amended) A process for the preparation of an amide derivative of the Formula la or Ib, or a pharmaceutically-acceptable salt or <u>in-vivo</u>-cleavable ester thereof, according to claim 1 or claim 2 which comprises:-

(a) reacting an N-phenyl-2-aminobenzamide of the Formula II

$$(R^{1})_{m}$$
  $(R^{2})_{n}$   $(R^{2})_{q}$   $(R^{2})_{q}$ 

II

with a carboxylic acid of the Formula III, or a reactive derivative thereof,

wherein variable groups are as defined in claim 1 and wherein any functional group is protected if necessary, and:

X

Page 15

- (i) removing any protecting groups; and
- (ii) optionally forming a pharmaceutically-acceptable salt or in-vivo-cleavable ester;
- (b) reacting an aniline of the Formula X

$$(R^1)_m$$
 $N$ 
 $R^3$ 
 $(R^2)_n$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 

with a carboxylic acid of the Formula VI, or a reactive derivative thereof,

$$HO_2C - (CH_2)_q - Q$$
 VI

under standard amide bond forming conditions, wherein variable groups are as defined in claim 1 and wherein any functional group is protected if necessary, and:

- (i) removing any protecting groups; and
- (ii) optionally forming a pharmaceutically-acceptable salt or in-vivo-cleavable ester;
- (c) for the preparation of an amide derivative of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is (1-6C)alkoxy or substituted (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylamino, di-[(1-6C)alkyl]amino or substituted (1-6C)alkylamino, the alkylation, conveniently in the presence of a suitable base, of an amide derivative of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is hydroxy, mercapto or amino as appropriate;
- (d) for the preparation of an amide derivative of the Formula Ia wherein a substituent on Q is amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, substituted (1-6C)alkylamino or substituted N-(1-6C)alkyl-(2-6C)alkylamino, the reaction, conveniently in the presence of a suitable base, of an amide derivative of the Formula Ia wherein a substituent on Q is a suitable leaving group with an appropriate amine;
- (e) for the preparation of an amide derivative of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is (1-6C)alkanoylamino or substituted (2-6C)alkanoylamino, the acylation of a compound of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is amino;
- (f) for the preparation of an amide derivative of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is (1-6C)alkanesulphonylamino, the reaction of a compound of the



Page 16

Formula Ia wherein R<sup>1</sup> or a substituent on Q is amino with a (1-6C)alkanesulphonic acid, or an activated derivative thereof;

- (g) for the preparation of an amide derivative of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is carboxy, carboxy-(1-6C)alkyl, carboxy-(1-6C)alkoxy, carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-carboxy-(1-6C)alkylamino or carboxy-(2-6C)alkanoylamino, the cleavage of a compound of the Formula Ia wherein R<sup>1</sup> or a substituent on Q is (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl-(1-6C)alkyl, (1-6C)alkoxycarbonyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-(1-6C)alkylamino or (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino as appropriate; or
- (h) for the preparation of an amide derivative of the Formula Ia wherein R<sup>1</sup> is amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, the reaction, conveniently in the presence of a suitable base, of a compound of the Formula XIII

Z-(1-6C)alkyl 
$$X - (CH_2)_q - Q$$

wherein X,  $R^2$ ,  $R^3$ , n, q and Q have any of the meanings defined in claim 1 and Z is a suitable leaving group with an appropriate amine or heterocycle.

- 10. (Amended) A pharmaceutical composition which comprises an amide derivative of the Formula Ia or Ib, or a pharmaceutically-acceptable or <u>in-vivo</u>-cleavable ester thereof, as defined in any one of claims 1-3 and 5-8, in association with a pharmaceutically-acceptable diluent or carrier.
- 12. (Amended) A method of treating a disease or medical condition mediated by cytokines which comprises administering to a warm-blooded animal an effective amount of

B.

Application No.: 09/936,758

Page 17

an amide derivative of the Formula Ia or Ib, or a pharmaceutically-acceptable in-vivo-cleavable ester thereof, as defined in any one of claims 1-3 and 5-8. an amide derivative of the Formula Ia or Ib, or a pharmaceutically-acceptable salt or